BOLT Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. (BOLT) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $2.40 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -14.3% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.
Sector
Healthcare
Industry
Biotechnology